整合酶抑制剂初始抗逆转录病毒治疗与新发糖尿病及体重增加风险
在北美HIV队列(NA-ACCORD)中,比较初始INSTI、PI或NNRTI方案的新发糖尿病风险。
要点
- 初始INSTI方案与NNRTI相比新发糖尿病风险未见显著升高
- 初始PI方案较NNRTI新发糖尿病风险升高
- INSTI相关糖尿病风险可能通过体重增加介导
核心结论
- 初始cART使用INSTI或PI较NNRTI可能增加新发糖尿病风险,且该风险可能通过体重增加介导。
研究设计与样本
- 北美HIV队列(NA-ACCORD)中纳入22 884例≥18岁cART初治成人,2007年1月至2017年12月启动INSTI、PI或NNRTI方案,且治疗启动后12(±6)个月有体重测量。
主要发现
- 47%启动NNRTI、30%启动PI、23%启动INSTI方案,中位随访分别为3.0、2.3、1.6年。
- 总体722例(3%)发生糖尿病。
- 雷特格韦 vs NNRTI的HR为1.42(95%CI 1.06-1.91)。
临床怎么用
- 启动含INSTI或PI的初始cART时,应关注体重变化及糖尿病风险监测。
局限性
- 观察性队列设计,随访时间因方案组不同而异,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) is associated with greater weight gain among persons with human immunodeficiency virus (HIV), though metabolic consequences, such as diabetes mellitus (DM), are unclear. We examined the impact of initial cART regimen and weight on incident DM in a large North American HIV cohort (NA-ACCORD). METHODS: cART-naive adults (≥18 years) initiating INSTI-, protease inhibitor (PI)-, or nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens from January 2007 through December 2017 who had weight measured 12 (±6) months after treatment initiation contributed time until clinical DM, virologic failure, cART regimen switch, administrative close, death, or loss to follow-up. Multivariable Cox regression yielded adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident DM by cART class. Mediation analyses, with 12-month weight as mediator, similarly adjusted for all covariates. RESULTS: Among 22 884 eligible individuals, 47% started NNRTI-, 30% PI-, and 23% INSTI-based cART with median follow-up of 3.0, 2.3, and 1.6 years, respectively. Overall, 722 (3%) developed DM. Persons starting INSTIs vs NNRTIs had incident DM risk (HR, 1.17 [95% CI, .92-1.48]), similar to PI vs NNRTI initiators (HR, 1.27 [95% CI, 1.07-1.51]). This effect was most pronounced for raltegravir (HR, 1.42 [95% CI, 1.06-1.91]) vs NNRTI initiators. The INSTI-DM association was attenuated (HR, 1.03 [95% CI, .71-1.49] vs NNRTIs) when accounting for 12-month weight. CONCLUSIONS: Initiating first cART regimens with INSTIs or PIs vs NNRTIs may confer greater risk of DM, likely mediated through weight gain.
引用
- Rebeiro PF, Jenkins CA, Bian A, et al. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clin Infect Dis. 2021. PMID: 32936919. doi:10.1093/cid/ciaa1403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。